Founded in Boston, Massachusetts, Aprea Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel cancer therapeutics. The company's core mission is to forge new pathways in the fight against cancer by focusing on reactivating mutant p53 tumor suppressor proteins. Aprea's diversified portfolio includes both clinical and pre-clinical assets aimed at creating highly selective, potentially less toxic DDR-targeted therapeutics. Their market focus spans the United States and Sweden, addressing significant unmet medical needs for cancer patients with mutations in DNA damage response (DDR) genes.

Aprea Therapeutics has garnered attention for its innovative approach to precision oncology, which emphasizes efficacy without sacrificing tolerability. The company has attracted notable investors and affiliations within the biopharmaceutical industry, contributing to its credibility and growth. Key achievements include advancing several promising therapeutic candidates through various stages of clinical trials. Overall, Aprea's impact lies in its potential to revolutionize cancer treatment by offering more effective and less harmful options for patients with specific genetic mutations.